

# Influenza Vaccine Market, 2012 to 2023

<https://marketpublishers.com/r/11A4A2650BAEN.html>

Date: December 2017

Pages: 210

Price: US\$ 4,400.00 (Single User License)

ID: 11A4A2650BAEN

## Abstracts

Influenza is commonly known as “flu” or “seasonal flu” caused by influenza virus. The symptoms of influenza can be mild to severe ranging from fever to pneumonia. Influenza mainly affected by three type’s influenza virus, called type A, type B and type C. Influenza virus generally spread through the air by coughing and sneezing or touching contaminated surfaces by a virus. Influenza can be diagnosed by testing throat, sputum and nose. Numbers of rapid tests are available for detecting influenza virus. Influenza can be treated with antiviral drugs or prevented by administering influenza vaccine and several other fluid management methods. Influenza virus spreads around the world in yearly outbreaks that result in millions of severe illness and thousands of deaths across the world. WHO every year predicts few strains which are expected to circulate in following year, that allows pharmaceutical companies to develop influenza vaccine against these stains.

Recommendation by WHO and U.S’s Centers for Disease Control and Prevention (CDC) for yearly vaccination in high-risk group patients, cost of effectiveness of seasonal influenza vaccine in different age groups and settings expected to drive the market for influenza vaccine over the forecast period. Moreover reduced healthcare burden due to influenza vaccination expected to propel the market for influenza vaccine. For instance, in 2015-2016 influenza seasons, CDC estimates that influenza vaccination prevented approximately 5.1 million influenza illnesses, 2.5 million influenza-associated medical visits, and 71,000 influenza-associated hospitalizations. However, Influenza vaccine made in a year may not be effective in following year owing to evolving nature of influenza virus, in healthy individual influenza vaccine is modestly effective, sometimes new strain or overlooked strain become prevalent in that season, and product recalls which may hamper the uptake and growth influenza vaccine market.

Influenza Vaccines market has been segmented on the basis of vaccine type, strain type, formulation type, end user, and region

Based on vaccine type, Influenza Vaccines market segmented as follows:

Killed or Inactivated Vaccine

Live Vaccine

Based on strain type, Influenza Vaccines market segmented as follows:

Trivalent Influenza Vaccine

Quadrivalent Influenza Vaccine

Based on formulation type, Influenza Vaccines market segmented as follows:

Injections

Nasal Sprays

Based on distribution channel, Influenza Vaccines market segmented as follows:

Government Immunization programmes

Non Governmental Organizations (NGOs)

Hospitals

Clinics

Players in influenza vaccine market focusing on developing effective vaccine i.e. quadrivalent against influenza virus and eyeing on expanding geographic presence to increase the market revenue for influenza vaccine products. For Instance, in June 2016, Sanofi received a positive end of a procedure from the German which helps in getting market authorization for VaxigripTetra, a quadrivalent vaccine against influenza. Several leading players in influenza vaccine market shipping the vaccine to U.S. market to meet seasonal demand in the country. Securing government tenders has become essential for influenza vaccine manufacturers to gain larger market share and helps in sustaining the business. For instance, in 2015, Sinovac Biotech Ltd. received the tender award from Beijing government to supply seasonal influenza vaccine.

Influenza Vaccines market has been segmented into five regions Viz. North Americas, Europe, Asia Pacific, Latin America and the Middle East and Africa. Each year, there are two seasons of influenza because of northern and southern hemispheres have winter in different times. An occurrence of influenza infections high in developing countries than developed counters which make the market lucrative for players in

developing countries. However, Influenza vaccine market in North America expected to witness significant growth owing U.S.'s yearly vaccination programme. In Europe influenza vaccine limited to the high-risk groups rather than blanket vaccination programmes which market to grow at moderate growth rate. Asia Pacific market expected to grow at significant CAGR owing to increasing affordability, larger and subsidized immunization programs in several countries in the Asia region.

Some of the players in the influenza vaccines market include GlaxoSmithKline plc., Seqirus (CSL Limited), AstraZeneca, Sanofi Pasteur Inc., Sinovac Biotech Ltd., Novavax, Inc., DAIICHI SANKYO COMPANY, LIMITED., Mitsubishi Tanabe Pharma., Protein Sciences Corporation to name a few. There are several influenza vaccine candidates in a late-stage clinical pipeline which are expected hit the market in the forecast period. For instance, in 2017 Daiichi Sankyo's VN-100 and MEDI3250 influenza vaccine expected to get market approval in Japan.

In Jan 2016, CSL Limited acquired Novartis AG's influenza vaccine business in Germany, as a part of global influenza vaccine

In June 2016, Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has recommended not to use AstraZeneca's FluMist Quadrivalent Influenza vaccine in any settings owing to lack of statistically significant effectiveness in children

## Contents

### **1. EXECUTIVESUMMARY**

### **2. GLOBAL INFLUENZA VACCINES MARKET INTRODUCTION**

2.1. Global Influenza Vaccines market – Taxonomy

2.2. Global Influenza Vaccines market –Definitions

2.2.1. Vaccine Type

2.2.2. Strain Type

2.2.3. Formulation Type

2.2.4. Distribution Channel

2.2.5. Region

### **3. GLOBAL INFLUENZA VACCINES MARKET DYNAMICS**

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Influenza Vaccines market Dynamics – Factors Impact Analysis

3.6. Global Influenza Vaccines market – Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

3.6.4. China

3.7. Global Influenza Vaccines market – Product Innovations

3.8. Competitor Landscape

### **4. GLOBAL INFLUENZA VACCINES MARKET ANALYSIS, 2012-2016 AND FORECAST 2017 – 2023**

4.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Oppurtunity Analysis

### **5. GLOBAL INFLUENZA VACCINES MARKET , BY VACCINE TYPE, 2012 - 2023**

## 5.1. Killed or Inactivated Vaccine

5.1.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3. Market Opportunity Analysis

## 5.2. Live Vaccine

5.2.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

## **6. GLOBAL INFLUENZA VACCINES MARKET , BY STRAIN TYPE, 2016-2016 AND FORECAST 2017 - 2023**

### 6.1. Trivalent Influenza Vaccine

6.1.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.2.3. Market Opportunity Analysis

### 6.2. Quadrivaleant Influenza Vaccine

6.2.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.2.3. Market Opportunity Analysis

## **7. GLOBAL INFLUENZA VACCINES MARKET FORECAST, BY FORMULATION TYPE, 2012-2016 AND FORECAST 2017 - 2023**

### 7.1. Injections

7.1.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.1.3. Market Opportunity Analysis

### 7.2. Nasal Sprays

7.2.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.2.3. Market Opportunity Analysis

## **8. GLOBAL INFLUENZA VACCINES MARKET FORECAST, BY DISTRIBUTION**

## **CHANNEL, 2012-2016 AND FORECAST 2017 - 2023**

### 8.1. Government Immunization programmes

8.1.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.1.3. Market Opportunity Analysis

### 8.2. Non Governmental Organizations (NGOs)

8.2.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.2.3. Market Opportunity Analysis

### 8.3. Hospitals

8.3.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.3.3. Market Opportunity Analysis

### 8.4. Clinics

8.4.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.4.3. Market Opportunity Analysis

### 8.5. Clinics

8.5.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.5.3. Market Opportunity Analysis

## **9. GLOBAL INFLUENZA VACCINES MARKET FORECAST, BY REGION, 2012-2016 AND FORECAST 2017 - 2023**

### 9.1. North America

9.1.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)

9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

9.1.3. Market Opportunity Analysis

### 9.2. Europe

9.2.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)

9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

9.2.3. Market Opportunity Analysis

9.3. Asia-Pacific

9.3.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)

9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

9.3.3. Market Opportunity Analysis

9.4. Latin America

9.4.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)

9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

9.4.3. Market Opportunity Analysis

9.5. Middle East & Africa

9.5.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)

9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

9.5.3. Market Opportunity Analysis

9.6. Global Influenza Vaccines market - Opportunity Analysis Index, By Vaccine Type, Strain Type, Formulation Type, Distribution Channel and Region, 2012-2016 and Forecast 2017 – 2023

## **10. NORTH AMERICA INFLUENZA VACCINES MARKET ANALYSIS, 2012-2016 AND FORECAST 2017 - 2023**

10.1.1. Vaccine Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1.1. Killed or Inactivated Vaccine

10.1.1.2. Live Vaccine

10.1.2. Strain Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.2.1. Trivalent Influenza Vaccine

10.1.2.2. Quadrivaleant Influenza Vaccine

10.1.3. Formulation Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.3.1. Injections

10.1.3.2. Nasal Sprays

10.1.4. Distribution Channel Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.4.1. Government Immunization programmes



- 10.1.4.2. Non Governmental Organizations (NGOs)
- 10.1.4.3. Hospitals
- 10.1.4.4. Clinics
- 10.1.5. Country Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  - 10.1.5.1. U.S
  - 10.1.5.2. Canada
- 10.1.6. North America Influenza Vaccines market - Opportunity Analysis Index, By Vaccine Type, Strain Type, Formulation Type, Distribution Channel, and Country, 2012-2016 and Forecast 2017 – 2023
- 10.1.7. North America Influenza Vaccines market Dynamics - Trends

## **11. EUROPE INFLUENZA VACCINES MARKET ANALYSIS, 2012-2016 AND FORECAST 2017 - 2023**

- 11.1.1. Vaccine Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  - 11.1.1.1. Killed or Inactivated Vaccine
  - 11.1.1.2. Live Vaccine
- 11.1.2. Strain Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  - 11.1.2.1. Quadrivaleant Influenza Vaccine
- 11.1.2 Trivalent Influenza Vaccine
  - 11.1.2.1. Quadrivaleant Influenza Vaccine
- 11.1.3. Formulation Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  - 11.1.3.1. Injections
  - 11.1.3.2. Nasal Sprays
- 11.1.4. Distribution Channel Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  - 11.1.4.1. Government Immunization programmes
  - 11.1.4.2. Non Governmental Organizations (NGOs)
  - 11.1.4.3. Hospitals
  - 11.1.4.4. Clinics
- 11.1.5. Country Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  - 11.1.5.1. Germany
  - 11.1.5.2. UK
  - 11.1.5.3. France
  - 11.1.5.4. Italy



11.1.5.5. Spain

11.1.5.6. Poland

11.1.5.7. Russia

11.1.5.8. Rest of Europe

11.1.6. Europe Influenza Vaccines market - Opportunity Analysis Index, By Vaccine Type, Strain Type, Formulation Type, Distribution Channel, and Country, 2012-2016 and Forecast 2017 – 2023

11.1.7. Europe Influenza Vaccines market Dynamics - Trends

## **12. ASIA-PACIFIC INFLUENZA VACCINES MARKET ANALYSIS, 2012-2016 AND FORECAST 2017 - 2023**

12.1.1. Vaccine Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1.1. Killed or Inactivated Vaccine

12.1.1.2. Live Vaccine

12.1.2. Strain Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.2.1. Trivalent Influenza Vaccine

12.1.2.2. Quadrivalent Influenza Vaccine

12.1.3. Formulation Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.3.1. Injections

12.1.3.2. Nasal Sprays

12.1.4. Distribution Channel Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.4.1. Government Immunization programmes

12.1.4.2. Non Governmental Organizations (NGOs)

12.1.4.3. Hospitals

12.1.4.4. Clinics

12.1.5. Country Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.5.1. Japan

12.1.5.2. China

12.1.5.3. India

12.1.5.4. ASEAN

12.1.5.5. Australia & New Zealand

12.1.5.6. Rest of APAC

12.1.6. Asia-Pacific Influenza Vaccines market - Opportunity Analysis Index, By

Vaccine Type, Strain Type, Formulation Type, Distribution Channel, and Country, 2012-2016 and Forecast 2017 – 2023

12.1.7. Asia-Pacific Influenza Vaccines market Dynamics - Trends

### **13. LATIN AMERICA INFLUENZA VACCINES MARKET ANALYSIS, 2012-2016 AND FORECAST 2017 - 2023**

13.1.1. Vaccine Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1.1. Killed or Inactivated Vaccine

13.1.1.2. Live Vaccine

13.1.2. Strain Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.2.1. Trivalent Influenza Vaccine

13.1.2.2. Quadrivalent Influenza Vaccine

13.1.3. Formulation Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.3.1. Injections

13.1.3.2. Nasal Sprays

13.1.4. Distribution Channel Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.4.1. Government Immunization programmes

13.1.4.2. Non Governmental Organizations (NGOs)

13.1.4.3. Hospitals

13.1.4.4. Clinics

13.1.5. Country Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.5.1. Brazil

13.1.5.2. Mexico

13.1.5.3. Argentina

13.1.5.4. Venezuela

13.1.5.5. Rest of Latin America

13.1.6. Latin America Influenza Vaccines market - Opportunity Analysis Index, By Vaccine Type, Strain Type, Formulation Type, Distribution Channel, and Country, 2012-2016 and Forecast 2017 – 2023

13.1.7. Latin America Influenza Vaccines market Dynamics - Trends

### **14. MIDDLE EAST & AFRICA INFLUENZA VACCINES MARKET ANALYSIS, 2012-2016 AND FORECAST 2017 - 2023**

14.1.1. Vaccine Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

14.1.1.1. Killed or Inactivated Vaccine

14.1.1.2. Live Vaccine

14.1.2. Strain Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

14.1.2.1. Trivalent Influenza Vaccine

14.1.2.2. Quadrivaleant Influenza Vaccine

14.1.3. Formulation Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

14.1.3.1. Injections

14.1.3.2. Nasal Sprays

14.1.4. Distribution Channel Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

14.1.4.1. Government Immunization programmes

14.1.4.2. Non Governmental Organizations (NGOs)

14.1.4.3. Hospitals

14.1.4.4. Clinics

14.1.5. Country Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

14.1.5.1. Gulf Cooperation Council (GCC) Countries

14.1.5.2. Israel

14.1.5.3. South Africa

14.1.5.4. Rest of MEA

14.1.6. Middle East & Africa Influenza Vaccines market - Opportunity Analysis Index, By Vaccine Type, Strain Type, Formulation Type, Distribution Channel, and Country, 2012-2016 and Forecast 2017 – 2023

14.1.7. Middle East & Africa Dynamics - Trends

## **15. COMPETITION LANDSCAPE**

15.1. Strategic Dashboard of Top Market Players

15.2. Company Profiles (Introduction, Financial Analysis Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

15.2.1. GlaxoSmithKline, plc.

15.2.2. Seqirus (CSL Limited)

15.2.3. AstraZeneca

15.2.4. Sanofi

15.2.5. Sinovac Biotech Ltd

15.2.6. Novavax, Inc

15.2.7. DAIICHI SANKYO COMPANY, LIMITED

## **16. RESEARCH METHODOLOGY**

## **17. KEY ASSUMPTIONS AND ACRONYMS**

## I would like to order

Product name: Influenza Vaccine Market, 2012 to 2023

Product link: <https://marketpublishers.com/r/l1A4A2650BAEN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l1A4A2650BAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970